Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496994 | 0.88 | HTR2C (0.45) | HTR2CALDH1A1NAAATSHRTDP1 | |
| SCHEMBL2883395 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL28234487 | 0.85 | HTR2C (0.44) | HTR2CALDH1A1NAAATSHRTDP1 | |
| Hydrochloric Acid SCHEMBL28885388 | 0.84 | TSHR (0.41) | HTR2CALDH1A1NAAATSHRMEN1 | |
| SCHEMBL6682800 | 0.83 | HTR2C (0.50) | HTR2CALDH1A1NAAATSHRTDP1 | |
| SCHEMBL16917384 | 0.81 | MGAM (0.46) | ALDH1A1NAAATSHRTDP1MEN1 | |
| SCHEMBL27869299 | 0.81 | ADRA2A (0.50) | HTR2CALDH1A1NAAATSHRTDP1 | |
| SCHEMBL12157555 | 0.80 | MGAM (0.52) | HTR2CALDH1A1NAAATSHRTDP1 | |
| SCHEMBL20801668 | 0.80 | TSHR (0.38) | HTR2CALDH1A1TSHRDGKAKDM4E | |
| SCHEMBL2593332 | 0.80 | TSHR (0.38) | HTR2CALDH1A1TSHRDGKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3627988-B1 | STRUCTURALLY-COLORED ARTICLES AND METHODS FOR MAKING AND USING STRUCTURALLY-COLORED ARTICLES | NIKE INNOVATE CV (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2020-02-20 | — | — | US | disclosed |
| CN-100553639-C | Be used for the treatment of thrombotic boronic acid polyvalent salts | TRIGEN LTD (GB) | 2009-10-28 | — | — | CN | disclosed |
| US-20090130021-A1 | Methods, products and uses involving platelets and/or the vasculature | MUNCH GOTZ | 2009-05-21 | — | — | US | disclosed |
| CN-101392002-A | Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis | TRIGEN LTD (GB) | 2009-03-25 | — | — | CN | disclosed |
| CN-100447151-C | Borate and application thereof in preparing medicament for treating thrombosis | TRIGEN LTD (GB) | 2008-12-31 | — | — | CN | disclosed |
| EP-1824979-A2 | METHODS, PRODUCTS AND USES INVOLVING PLATELETS AND/OR THE VASCULATURE | Trigen GmbH (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061650-A2 | METHODS, PRODUCTS AND USES INVOLVING PLATELETS AND/OR THE VASCULATURE | TRIGEN GMBH (DE) | 2006-06-15 | — | — | WO | disclosed |
| CN-1146575-C | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ��λҩƷ��˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0960108-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-12-01 | — | — | EP | disclosed |
| US-5827860-A | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5827866-A | ANTICOAGULANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | disclosed |
| WO-1998033788-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-06 | — | — | WO | disclosed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HTR2C 1902/4885ALDH1A1 514/4885NAAA 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.